Neurocrine Biosciences to Host R&D Day on December 16

SAN DIEGO , Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m.

PRNewsWire • Dec 9, 2025

Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level

Neurocrine Biosciences stock, part of the high-ranking biotech industry group, is trading back inside a buy zone.

Investors Business Daily • Dec 5, 2025

Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 2, 2025

Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now

Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • Nov 27, 2025

Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules

Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration and robust clinical data across diverse patient populations and concludes that VMAT2 inhibitors are not clinically interchangeable Publication provides a comprehensive resource containing clinical study results, safety profiles and use considerations to support treatment decisions SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, pharmacokinetic and more than a decade of clinical research on two FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors – INGREZZA® (valbenazine) capsules and deutetrabenazine – for the treatment of tardive dyskinesia. Among key insights, the review highlights the distinct profiles of VMAT2 inhibitors approved for tardive dyskinesia and presents unique attributes of INGREZZA: selectivity to VMAT2, a therapeutic response at the lowest available 40 mg dose and data across a wide range of patient populations.

PRNewsWire • Nov 20, 2025

Nvidia Earnings Pivot? 5 Best Stocks For Sector Rotation Out Of Tech

Nvidia earnings have cast a light on defensive areas, inducing a sector rotation that may accelerate in the short term. Looking beyond NVDA earnings, an economic environment characterized by slowing growth, persistent inflation, and tariff uncertainty is compelling investors to look beyond overbought tech. This shift favors sectors that offer resilience, stable cash flow, and intrinsic value over speculative future growth.

Seeking Alpha • Nov 19, 2025

Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Neurocrine Biosciences, Inc. ( NBIX ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Kyle Gano - CEO & Director Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Phoebe Tan - Jefferies LLC, Research Division Presentation Phoebe Tan Jefferies LLC, Research Division Hi, everyone. My name is Phoebe Tan, and I am an Associate on Akash Tewari's team.

Seeking Alpha • Nov 18, 2025

A Strong Crenessity Launch And Muscarinic Pipeline Can Propel Neurocrine Biosciences Further

Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with increased marketing, while Crenessity's rapid uptake suggests over $1B in peak revenue potential. The late-stage pipeline, including direclidine and osavampator, offers high-risk/high-reward opportunities that could significantly boost NBIX's value.

Seeking Alpha • Nov 19, 2025

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile

On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it was generally well tolerated.

Benzinga • Nov 11, 2025

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Nov 11, 2025